Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
about
The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in ChinaImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisInnovative agents in multiple myelomaAmyloid diseases of the heart: current and future therapiesRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisRare and unusual clinicopathologic presentation of renal AL amyloidosis.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionAmyloidosis and POEMS syndrome.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chainChronic diarrhea as the presenting feature of primary systemic AL amyloidosis: serendipity or delayed diagnosis?Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialAmyloidosis: pathogenesis and new therapeutic options.Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsTherapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ InvolvementActivity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Protein post-translational modifications and misfolding: new concepts in heart failure.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosisTargeting protein aggregation for the treatment of degenerative diseasesNeuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.The amyloidoses: clinical features, diagnosis and treatment.Al amyloidosisOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisLenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.The multi-target effects of CNI-1493: convergence of anti-amylodogenic and anti-inflammatory properties in animal models of Alzheimer's diseasePredictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.
P2860
Q26740439-7481F144-0F85-4064-B361-FA536D4175C1Q26827340-9B0F3883-4EDD-4956-9778-9A17AAF61F30Q26829735-3873DF4D-6C0E-4B99-91AD-578E4FFDC610Q27022493-5FFA1BB1-2E73-42D9-A05C-5D4B8601AD3BQ27023836-F19F269C-51AE-4827-9DC2-6B129AE17EEBQ28069975-B8AE198B-ED2C-475F-80F0-D833472612ECQ30383707-C0DAC98D-9AFD-4B06-B424-54497C95DFBEQ33417805-410DE11A-94B3-4402-BBDE-258730D17C59Q33427726-0F185855-D167-4436-9060-C5AFB7E181CFQ33795363-511BE7FF-3D71-453B-92AB-CBBAEFDEDA9CQ33867198-C578E05A-9AB1-4015-A1CC-94BBE6AAB81CQ34353682-1285284B-898D-4A7E-9BAB-3EC1A2A68ABAQ34448455-F17AD064-93C5-4698-A903-CCEFB167BD27Q34450910-9B28A475-E8A7-4832-BEF9-E12864D02486Q34555067-75BD4818-B0CC-4790-9EEC-6F51BB9D9C56Q34583702-37EFF21F-FB76-4B05-B68C-CC3033FFBD19Q34687304-BC98CA86-6063-4D11-AF19-C82357325459Q34768284-A4F3BE20-3B50-424D-800C-1C5EF250949DQ35025410-168F88F9-F950-497D-8CFF-DEEBD8CE672EQ35081363-6B36F27A-1D13-4F4A-A1C0-EDC6AC92B203Q35111771-256D38B4-EEF6-4852-BD49-EB3338D54E3AQ35208216-326794F0-FFE1-4EA9-91FF-9459B548F44FQ35485742-8B14C195-2918-4AD7-9A85-BB539362C74AQ35895152-B6D45451-CEC7-43C9-85E5-E02ED4ADC8A7Q36009723-A5166A3A-8F4F-4F37-828D-E4CA436F452DQ36015183-4776E199-18BC-4D3B-96B1-8645F88CC53EQ36028759-DF15C9F4-BD8D-4512-B26E-D1D01CF5E484Q36036322-804D8C83-8002-456C-91E3-0F3A8CADAE8DQ36163205-F1486F84-8293-42B0-A200-A30791518113Q36199790-E7B6B367-AED5-4630-9773-57435C6864E9Q36235980-0B0B2C28-FD33-4962-B481-0D6C638E0DCCQ36302859-F6834B28-D22B-4245-9935-A477742F361EQ36366997-33EE6B1C-28BC-43B2-925D-25FA4286C2A9Q36392233-9C14BC98-A49B-4872-94A6-95BE5E684054Q36779777-00E9A8EA-32F0-46CF-86F0-E537D0A9A208Q36910372-6A414762-580E-491E-8395-8B3C5454E9ADQ37172003-003E2726-7F3D-4555-85D0-082FB19225A0Q37212712-ECB383D1-94FB-4308-87AB-AA3F6B111E25Q37541047-2F7CD690-544C-4D99-84C5-A2328EA4CB37Q37624857-28E664F6-403D-4285-AE49-6DCDDFAC0635
P2860
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
@en
Bortezomib with or without dexamethasone in primary systemic
@nl
type
label
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
@en
Bortezomib with or without dexamethasone in primary systemic
@nl
prefLabel
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
@en
Bortezomib with or without dexamethasone in primary systemic
@nl
P2093
P50
P356
P1476
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
@en
P2093
Ashutosh D Wechalekar
Julian D Gillmore
Philip N Hawkins
Vittorio Perfetti
P304
P356
10.1200/JCO.2009.23.8220
P407
P577
2010-01-19T00:00:00Z